CB2 modulators have potential treatment capability for inflammatory,pain, neurodegenerative disorders, osteoporosis, fibrotic conditions,and cancers.15−19 Recently, several synthetic CB2-selective ligands have been reported;20−28 however, few have undergone clinical trials, and none have yet gainedFDA approval. The gene discussed is CNR2; the disease is osteoporosis.